Introduction
On 20 December 1984 Mr John Patten, then parliamentary secretary for health, announced that regional health authorities in England and Wales had been set a target ofaccepting at least 40 new patients with renal disease per million population by 1987.' It appears that this target is the beginning ofan incremental scale since the minister stated that it was "the government's intention that the provision of renal services will continue to expand after 1987." The target for Wales is 50 patients per million population. 2 Some regions had reached the target by the close of 1984, but most fell short (table I) . In all regions the need for planning was accepted in order that sufficient resources and personnel were allocated. Several regions have been interested in the use of mathematical models to predict the numbers of patients with end Regional health authority   patients  haemodialysis haemodialysis  dialysis  Graft  patients  haemodialysis haemodialysis  dialysis  Graft   East Anglia  144-7  30-0  27-4  1-6  85-8  244-2  57-9  29-5  A-7  153-2  Mersey  107-5  19-6  38-8  9-2  40-0  186-7  38-8  27-1  18-8  102-1  Northern  140-3  41-6  24-2  13-2  61-3  231-9  58-2  31-9  59-0  92-9  North Western  75-3  11-8  25-0  1-5  37-0  174-3  24-8  41-0  35-3  73-3   Oxford   118-3  15-8  42-9  3-3  56-3  214-2  23-8  52-9  24-2  113-3  South Western   110-0  18-1  51-6  6-8  33-5  185-2  20-6  52-9  33-2 Continuous ambulatory peritoneal dialysis has not been considered separately. The model accounts for this treatment as a substitute for independent home haemodialysis, for which running costs are similar. Some patients are treated by continuous peritoneal dialysis who would otherwise require supported haemodialysis, but it is assumed that at steady state the number will not be large enough to distort the model seriously.
Survival analyses on the UK database showed that mean life expectancy in standard risk patients was approximately 111/2 years and in high risk patients six years. Our model incorporates refined subsets of these data and also a "natural" mortality factor to account for the reduced natural life span of older patients. Patients who changed treatment were considered lost to observation from the date of the change so that the life expectancy for each type of treatment is stated separately. The reduced life expectancies for the "failed graft" patient allow for the time he or she will have spent with a successful transplant. It was necessary to extrapolate beyond the length of the 10 year survival analyses to reach mean survival points, so our life expectancy calculations (table III) necessarily rely on data that are up to 10 years old. They must be underestimates because of improvements Discussion Our approach describes the steady state stage of numbers of patients and use of resources in the treatment of renal failure. Any model may become less stable if there are new treatments. The introduction of continuous ambulatory peritoneal dialysis and the improvements in transplantation coincident with the introduction of cyclosporin have made a big impact on the pattern of treatment for end stage renal failure and established fresh momenta in the system. Our model is built on current knowledge and observed results, and we believe that our calculations of the impact of continuous ambulatory peritoneal dialysis and of cyclosporin on graft survival will suffice for the model to represent adequately the likely outcome.
There are many approaches to assessing cost: "total," "average," "marginal," and "worths." We believe that the most important measure is the overall cost of treating a mix of patients by an integrated programme of different treatments. Treatment for renal failure does not lend itself to a choice of alternative treatments on economic grounds alone. The changing medical and social needs of the patient dictate the treatment pattern. There is one choice only:
to treat or not to treat.
Our analyses are based on an assumption of the fulfilment of a national target oftreating 40 new patients per million population per year with end stage renal failure, equivalent to 1982 patients for England and Wales. We have made no allowance for the spare capacity that exists in all systems if they are to work effectively. Hospital haemodialysis is provided on a planned basis and can operate at high utilisation rates, but any attempt to operate a dialysis unit full out round the clock imposes impossibly high demands'2 and can be dangerous. The cost of operating the transplant unit represents a small part of the total (some 5%) so the assumption of full bed occupancy here makes little difference to the actual costs. Staff overheads are determined by the need to provide for dialysis and transplantation and also to support the use of back up beds for intercurrent problems. The lower cost of achieving outpatient status with continuous ambulatory peritoneal dialysis compared to home haemodialysis must be weighed against the higher cost of readmission for intercurrent care.
The national model predicts an expenditure of £3-Im per million population at a steady state resulting from an intake of 40 new patients per million population per year. Any increase in this intake means more high risk patients. The corresponding figures are £3-6m and £4-2m for intakes of 50 and 60 new patients with a mix of standard and high risk category patients as given above. Dowie estimated that the annual expenditure was £Em per million population in England and Wales in 1981-2.'3 It appears that regional health authorities will have to budget for a considerable rise in costs for the treatment of end stage renal failure over the next few years as more patients are accepted into the programme, building up towards the steady state. Table VI gives the average annual cost per patient group. Since most patients are managed by a sequence of treatments, average annual costs for one treatment only are of limited value. Nevertheless, they show the differences in cost ofthe different types of treatments and allow immediate comparison with Mancini's average figures of £11 200 to £13 650 for hospital haemodialysis and £7100 to £8700 for home dialysis at November 1981 prices-'-a time when few high risk patients were treated.
Any improvement in survival increases the overall cost of the programme by the need for more drugs, disposable and fixed equipment, and back up services. A one month improvement in life expectancy with hospital haemodialysis treatment increased the programme cost by roughly six times as much as a similar increase in graft survival. Thus the model points to the primary role that transplantation must have in the strategy of regional programmes and emphasises that this reduces the overall cost of the programme by about £30 000 for each successful transplant.
These predictions should help to establish a minimum requirement of facilities and personnel to fulfil the national target for the treatment of end stage renal failure. The resource implications are considerable, but it must be remembered that 16 European countries accepted over 40 new patients per million population in 1984.' In each of these countries the patient with end stage renal failure already had a better chance in 1984 than it is hoped he or she will have in England and Wales by 1987.
MATERIA NON MEDICA Innocent tyranny?
Often we used to wonder why he so proudly caressed his long, greyish beard while talking to everyone. He was hale and hearty at 59 years, and now and then we saw him with the surgery chief but only lately realised that he was hiding a large goitre underneath his beard. He was persuaded to undergo surgery and was admitted.
At the preoperative preparation he vehemently refused to part-with the almost age long association with his beard. We were amused and scornful. The chief was called, with whom he could not argue. But his clean shaven face only made his dejection more obvious. He looked into the mirror, sighed, and was silent after that. Over the next few minutes he complained of severe chest pain and collapsed. All resuscitative measures failed.
While signing the death certificates I wondered ifthyroid surgery could be done with the beard on; but then so many bearded men have been shaved before operations. We understood that he liked his beard but how were we to know that he valued it so much that he'd die? Were we, or were we not guilty of an offence? The barber seemed to share our guilt.-sHrAM s KOTHARI, JESURAJ LIONEL, Vellore, India.
Strict quarantine
When I was 11 in 1920 1 had chickenpox-very badly.
"Whatever you do, don't let your little sister come past the door," they said to me. And I didn't.
For the first day or two there was no temptation, I felt so rotten. But as time went by I asked for the door of my bedroom to be left open so that I could hear what was going on in the house, and that allowed lovely conversations with my 6 year old sister when no one was around to see. But I never let her past the door.
Adults came to see me and they got in. Some of them brought presents. Grandpa brought me a silver threepenny bit. Wealth! But no freedom to go shopping.... A problem easily solved.
I summoned my sister when the coast was clear and transferred the coin from my hot and sticky hand to hers. But I never allowed her over the threshold. Then I sent her off to the sweetie shop with strict instructions as to what I required. When she got back I recompensed her for her trouble. I counted out 12 aniseed balls, tore a strip off the liquorice strap, and divided the bag of popcorn in two. These delights I pressed into her eager outstretched paln at the doorway. But I didn't let her in.
And she didn't take chickenpox. So the quarantine instructions must have been quite right.-MuRIEL J F BARNETT, Edinburgh.
